The findings are now making the rounds in the medical world, and everyone is stunned by the trial results. Speaking to the media, Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, said that the complete remission in every patient is "unheard-of." He labelled the research a world-first.
Digital Desk: A small group of people with rectal
cancer experienced something of a miracle as their cancer miraculously vanished
after experimental treatment.
According
to a New York Times report, in a very small clinical trial, 18 patients took a
drug called "Dostarlimab" for around six months. In the end, every
one of them saw their tumours disappear, which was magical and historic.
All 18 rectal cancer patients were
given the same drug, which is called "Dostarlimab". As a result of
the treatment, cancer was completely obliterated in every patient -
undetectable by physical exams, endoscopy, positron emission tomography, PET
scans, or MRI scans.
Dr. Luis A. Diaz J. of New York's
Memorial Sloan Kettering Cancer Center exclaimed in joy and stated that this happened
for the first time in the history of Cancer." As per reports, the patients
involved in the clinical trial faced exhausting previous treatments to get rid
of their cancer, such as chemotherapy, radiation, and invasive surgery that
could result in bowel, urinary, and even sexual dysfunction. The 18 patients
went into the trial expecting the same painful process. To their surprise, no
further treatment was needed, and they were completely fine.
The findings are now making the rounds
in the medical world, and everyone is stunned by the trial results. Speaking to
the media, Dr. Alan P. Venook, a colorectal cancer specialist at the University
of California, said that the complete remission in every patient is
"unheard-of." He labelled the research a world-first.
Dr. Andrea Cercek, co-author of the
paper, described the moment patients learned they were cancer-free."There
were a lot of happy tears," she told the media.
During the trial, patients took
Dostarlimab every three weeks for six months. They were all in similar stages
of their cancer-it was locally advanced in the rectum but had not outspread to
other organs.
The cancer researchers who reviewed
the drug told the media that the treatment looks promising, but a larger-scale
trial is required to see if it will work for more patients and if the cancers
are truly in remission.
